HTN, CHF, reduction of mortality after MI. Prevention of MI, stroke or CV death & reduction of need for revascularization procedures in patients w/ increased CV risk. Decrease progression of renal insufficiency in nondiabetic & diabetic overt nephropathy. Prevention of MI, stroke or CV death in diabetic patients. Reduce albumin excretion in nondiabetic & diabetic incipient nephropathy.